US2002090368A1PendingUtilityA1

Therapeutic uses of bactericidal/permeability increasing (BPI) protein products

50
Assignee: XOMA CORPPriority: Mar 12, 1993Filed: Aug 27, 2001Published: Jul 11, 2002
Est. expiryMar 12, 2013(expired)· nominal 20-yr term from priority
Inventors:Roger G. Little
A61P 7/04A61P 43/00A61P 35/00A61P 9/00A61P 29/00A61P 27/02A61P 13/02A61P 15/00A61P 19/02C07K 14/4742A61P 15/18A61P 15/16A61K 38/1751
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for neutralizing the anti-coagulant effect of heparin comprising administering to a subject an effective amount of a heparin binding BPI protein product.  
     
     
         2 . A method of inhibiting angiogenesis comprising administering to a subject an amount of a BPI protein product effective to inhibit angiogenesis.  
     
     
         3 . A method for neutralizing the anti-coagulant effect of heparin in a fluid sample comprising contacting said sample with an effective amount of heparin binding BPI protein product.  
     
     
         4 . The method of  claim 2  wherein the angiogenesis inhibited is associated with ocular retinopathy.  
     
     
         5 . A method for inhibiting endothelial cell proliferation comprising administering to a subject an amount of a BPI protein product effective to inhibit proliferation.  
     
     
         6 . A method of treating endometriosis comprising administering an amount of BPI to the endometrium effective to inhibit endothelial cell proliferation.  
     
     
         7 . A method for contraception comprising administering to a subject an amount of a BPI protein product to the uterine lining effective to prevent endothelial cell proliferation associated with implantation of a fertilized ovum.  
     
     
         8 . A method for inhibiting malignant tumor cell proliferation comprising administering to a subject an amount of a BPI protein product effective to inhibit proliferation.  
     
     
         9 . The method of  claim 8  wherein the malignant tumor is Kaposi's sarcoma.  
     
     
         10 . A method for treating a chronic inflammatory disease state comprising administering to a subject an amount of a BPI protein product effective to reduce inflammation.  
     
     
         11 . The method of  claim 10  wherein the chronic inflammatory disease is arthritis.  
     
     
         12 . The method of  claim 11  wherein the arthritic inflammatory disease state is rheumatoid arthritis.  
     
     
         13 . The method of  claim 11  wherein the arthritic inflammatory disease state treated is reactive arthritis.  
     
     
         14 . The method of claims  1 ,  2 ,  5 ,  6 ,  7 ,  8  and  10  wherein the BPI protein product is a 23-25 kD amino-terminal fragment of bactericidal/permeability-increasing protein.  
     
     
         15 . A method of inhibiting antiogenesis comprising administering to a subject an amount of a BPI protein product effective to inhibit angiogenesis.  
     
     
         16 . The method of  claim 15  wherein the angiogenesis inhibited is associated with ocular retinopathy.  
     
     
         17 . A method for inhibiting endothelial cell proliferation comprising administering to a subject an amount of a bactericidal/permeability increasing (BPI) protein product effective to inhibit proliferation of endothelial cells.  
     
     
         18 . A method of treating endometriosis comprising administering an amount of BPI to the endometrium effective to inhibit endothelial cell proliferation.  
     
     
         19 . A method for contraception comprising administering to a subject an amount of a BPI protein product to the uterine lining effective to provent endothelial cell proliferation associated with implantation of a fertilized ovum.  
     
     
         20 . A method of inhibiting malignant tumor cell proliferation comprising administering to a subject an amount of a BPI protein product effective to inhibit proliferation.  
     
     
         21 . The method of  claim 20  wherein the malignant tumor is Kaposi's sarcoma.  
     
     
         22 . The method of  claim 17  wherein the BPI protein product is an approximately 21 to 25 kD amino-terminal fragment of BPI protein.

Join the waitlist — get patent alerts

Track US2002090368A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.